PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29186917-5 2017 Lazabemide is a monoamine oxidase (MAO)-B inhibitor, a class of compounds that slows the depletion of dopamine stores in Parkinson"s disease and elevates dopamine levels produced by exogenously administered l-dopa. Levodopa 207-213 monoamine oxidase B Mus musculus 16-41 18286173-2 2008 The MAO-B inhibitor deprenyl, a long-standing antiparkinsonian therapy, is currently used clinically in concert with the dopamine precursor L-DOPA. Levodopa 140-146 monoamine oxidase B Mus musculus 4-9 11980384-13 2002 ), a MAO-B inhibitor potentiated the motor stimulant actions of subthreshold doses of the L-DOPA (100 mg/kg i.p.) Levodopa 90-96 monoamine oxidase B Mus musculus 5-10 11980384-19 2002 It is concluded that COMT and MAO-B enzymes play an important role in the metabolism of dopamine and administration of a COMT or MAO-B inhibitor may prove to be a better adjunct to L-DOPA therapy than a dopamine receptor agonist in Parkinson"s disease. Levodopa 181-187 monoamine oxidase B Mus musculus 129-134 31584763-1 2019 Monoamine oxidase B inhibitors are used in the treatment of this disease concomitantly with levodopa or as monotherapy. Levodopa 92-100 monoamine oxidase B Mus musculus 0-19